Clinical trial
Phase II Trial of Capecitabine for the Treatment of Unresectable/ Metastatic or…
NCT00464295 · Aga Khan University, Other · Completed
Key facts
| NCT number | NCT00464295 |
|---|---|
| Title | Phase II Trial of Capecitabine for the Treatment of Unresectable/ Metastatic or Advanced Hepatocellular Carcinoma(HCC) |
| Official title | Phase II Trial of Capecitabine for the Treatment of Unresectable/ Metastatic or Advanced Hepatocellular Carcinoma(HCC) |
| Acronym | HCC-CAP |
| Lead sponsor | Aga Khan University, Other |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Carcinoma, Hepatocellular |
| Intervention type | Drug |
| Interventions | Capecitabine in HCC |
| Enrollment | 15 |
| Start date | Aug 1, 2006 |
| Completion | Oct 1, 2007 |
| First posted | Apr 23, 2007 |
| Last update posted | Dec 14, 2007 |
| Countries | Pakistan |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: